Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Enterprise Value to EBITDA (EV/EBITDA)

Microsoft Excel

Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)

Cytokinetics Inc., EBITDA calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net loss (388,955) (215,314) (127,290) (121,692) (106,289)
Add: Income tax expense
Earnings before tax (EBT) (388,955) (215,314) (127,290) (121,692) (106,289)
Add: Interest expense 19,414 16,440 15,963 6,623 3,797
Earnings before interest and tax (EBIT) (369,541) (198,874) (111,327) (115,069) (102,492)
Add: Depreciation of property and equipment 5,814 2,276 1,831 1,293 1,239
Earnings before interest, tax, depreciation and amortization (EBITDA) (363,727) (196,598) (109,496) (113,776) (101,253)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Item Description The company
EBITDA To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. Cytokinetics Inc. EBITDA decreased from 2020 to 2021 and from 2021 to 2022.

Enterprise Value to EBITDA Ratio, Current

Cytokinetics Inc., current EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in thousands)
Enterprise value (EV) 13,914,826
Earnings before interest, tax, depreciation and amortization (EBITDA) (363,727)
Valuation Ratio
EV/EBITDA
Benchmarks
EV/EBITDA, Competitors1
AbbVie Inc. 28.01
Amgen Inc. 16.07
Bristol-Myers Squibb Co. 49.30
Danaher Corp. 21.35
Eli Lilly & Co. 51.12
Gilead Sciences Inc. 35.32
Johnson & Johnson 16.02
Merck & Co. Inc. 9.40
Pfizer Inc. 10.03
Regeneron Pharmaceuticals Inc. 11.37
Thermo Fisher Scientific Inc. 17.66
Vertex Pharmaceuticals Inc. 243.25
EV/EBITDA, Sector
Pharmaceuticals, Biotechnology & Life Sciences 15.25
EV/EBITDA, Industry
Health Care 15.32

Based on: 10-K (reporting date: 2022-12-31).

1 Click competitor name to see calculations.

If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.


Enterprise Value to EBITDA Ratio, Historical

Cytokinetics Inc., historical EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Enterprise value (EV)1 3,931,450 2,644,163 1,003,554 787,578 173,561
Earnings before interest, tax, depreciation and amortization (EBITDA)2 (363,727) (196,598) (109,496) (113,776) (101,253)
Valuation Ratio
EV/EBITDA3
Benchmarks
EV/EBITDA, Competitors4
AbbVie Inc. 13.31 13.44 21.34
Amgen Inc. 12.97 13.22 12.24
Bristol-Myers Squibb Co. 9.46 8.65 34.35
Danaher Corp. 18.42 21.05 26.68
Eli Lilly & Co. 37.74 29.85 23.67
Gilead Sciences Inc. 13.89 8.57 24.90
Johnson & Johnson 14.78 14.47 18.20
Merck & Co. Inc. 13.91 12.18 16.05
Pfizer Inc. 6.12 8.64 15.78
Regeneron Pharmaceuticals Inc. 15.27 6.68 12.70
Thermo Fisher Scientific Inc. 20.25 20.21 18.72
Vertex Pharmaceuticals Inc. 14.91 18.92 14.81
EV/EBITDA, Sector
Pharmaceuticals, Biotechnology & Life Sciences 13.58 13.16 18.90
EV/EBITDA, Industry
Health Care 13.71 13.87 16.50

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 See details »

2 See details »

3 2022 Calculation
EV/EBITDA = EV ÷ EBITDA
= 3,931,450 ÷ -363,727 =

4 Click competitor name to see calculations.